BI 764198, Placebo to match BI 764198, BI 764198, BI 764198 clinical trials

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis.

This study is looking into a new medicine, BI 764198, for people with a kidney condition called focal segmental glomerulosclerosis. We want to see if it helps reduce protein in the urine and if it's safe to use, compared to a dummy pill.